Artificial Intelligence in Life Sciences Market Size, Share, Growth, and Industry Analysis, By Type (Machine Learning,Deep Learning), By Application (Target Discovery,Drug Discovery), Regional Insights and Forecast to 2035

Artificial Intelligence in Life Sciences Market Overview

The global Artificial Intelligence in Life Sciences Market is forecast to expand from USD 4205.31 million in 2026 to USD 5416.44 million in 2027, and is expected to reach USD 31859.18 million by 2035, growing at a CAGR of 28.8% over the forecast period.

In 2024, the artificial intelligence in life sciences market market registered deployment across more than 1200 commercial platforms worldwide. Around 55 percent of adoption was concentrated in software solutions, while hardware contributed 15 percent and services 30 percent. Drug discovery commanded 32 percent of total application share, followed by diagnostics and omics analytics at 22 percent each. North America accounted for 49 percent of global participation in 2024, driven by more than 500 institutional deployments. Asia-Pacific expanded fastest, with over 200 new installations in 2024 alone. These facts highlight the rising significance of artificial intelligence in life sciences market market growth.

The United States is the dominant national market within the artificial intelligence in life sciences market industry report. In 2024, the U.S. represented 48.6 percent of North America’s share, equal to roughly 240 large-scale AI deployments across biotech and pharmaceutical firms. More than 300 AI-driven collaborations were launched in 2023 across U.S. companies. Clinical trial optimization accounted for 25 percent of U.S. AI adoption, while drug discovery commanded 35 percent. U.S. biopharma allocated more than 10 percent of R&D budgets to AI in 2024. These developments reflect the leadership role of the U.S. in artificial intelligence in life sciences market market analysis.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 32 percent of global adoption is linked to AI-driven drug discovery, while 20 percent stems from omics data analytics.
• Major Market Restraint: Only 6 percent of clinical datasets meet FAIR data standards; 10 percent of labs cite poor quality.
• Emerging Trends: Generative and foundation models reached 42 percent share of technology in 2024; hybrid architectures 25 percent.
• Regional Leadership: North America maintained 49 percent share; Asia-Pacific captured 25 percent; Europe retained 22 percent.
• Competitive Landscape: Top 10 companies captured 40 percent market share; small firms accounted for 60 percent.
• Market Segmentation: Software comprised 55 percent; services 30 percent; hardware 15 percent; drug discovery 32 percent.
• Recent Development: Biopharma commanded 54 percent end user share; cloud platforms reached 58 percent; AI startups grew 28 percent.

Artificial Intelligence in Life Sciences Market Latest Trends

Artificial intelligence in life sciences market market trends reflect the convergence of advanced algorithms, scalable compute, and collaborative data ecosystems. In 2024, 42 percent of adoption was captured by generative AI and foundation model platforms, with widespread application in molecular discovery and protein structure prediction. Cloud-based deployment represented 58 percent of all installations, compared to 30 percent for hybrid systems and 12 percent for on-premise solutions. Biopharma firms accounted for 54 percent of end-user demand, equivalent to more than 600 deployments in 2024. Clinical trial optimization platforms grew by 20 percent, with 150 pilots conducted globally in 2023.

Artificial Intelligence in Life Sciences Market Dynamics

DRIVER

"Expanding AI adoption in drug discovery and omics analytics"

Drug discovery platforms accounted for 32 percent of total application share in 2024, with more than 300 AI-driven collaborations launched in 2023. AI-driven omics analysis represented 22 percent of market usage, supported by a 45 percent increase in model deployments between 2023 and 2024. Foundation models reduced molecule design timelines by 30 percent compared to traditional screening. In the U.S., more than 200 AI consortia integrated machine learning into preclinical design pipelines. This demand accelerates expansion of the artificial intelligence in life sciences market market growth.

RESTRAINT

"Limited data quality and regulatory barriers"

Only 6 percent of clinical datasets met FAIR (findability, accessibility, interoperability, reusability) standards in 2024, leaving 94 percent with gaps in annotation and structure. Roughly 10 percent of labs reported unreliable results due to heterogeneous data. About 15 percent of AI systems faced integration challenges with legacy EHR platforms. Regulatory uncertainty delayed deployment in 12 percent of global jurisdictions. Intellectual property restrictions affected 8 percent of cross-licensed models. These restraints limit adoption, slowing artificial intelligence in life sciences market market forecast.

OPPORTUNITY

"Personalized medicine and AI diagnostics"

Personalized medicine now accounts for 20 percent of AI use cases in life sciences. AI diagnostic applications grew 25 percent in 2024 across oncology, neurology, and cardiology. More than 50 multi-omics AI platforms were launched globally by 2025. Translational platforms bridging preclinical and clinical domains captured 15 percent of vendor pipelines. Adoption in Asia, Latin America, and Africa remains below 10 percent, representing untapped opportunities. These figures illustrate substantial scope for artificial intelligence in life sciences market market opportunities.

CHALLENGE

"Model explainability, cost, and scaling"

About 8 percent of AI models failed validation in blinded clinical trials in 2024. Over 25 percent of organizations demanded explainable AI features, yet black-box models dominated 70 percent of systems. Only 7 percent of pilot projects scaled to more than 1,000 patients. Annual capital costs of AI infrastructure exceeded USD 5 million for major biotech companies. Trust concerns delayed adoption in 15 percent of conservative pharma divisions. These challenges reflect barriers within artificial intelligence in life sciences market industry analysis.

Artificial Intelligence in Life Sciences Market Segmentation

The artificial intelligence in life sciences market market is divided into type (machine learning and deep learning) and application (target discovery and drug discovery). Machine learning accounted for 29.6 percent of share in 2024, while deep learning held 42 percent. Drug discovery dominated with 32 percent of application share, and target discovery contributed 20 percent. This segmentation frames investment patterns and strategy within artificial intelligence in life sciences market market research report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Machine Learning: Machine learning methods accounted for 29.6 percent of technology share in 2024. More than 60 percent of AI platforms in pharma continue to rely on classical algorithms such as random forests and gradient boosting. Approximately 25 percent of regulatory filings included ML-driven models for biomarker classification. Adoption of ML-based tools in toxicity prediction increased 15 percent in 2024. Machine learning remains integral in artificial intelligence in life sciences market industry report.

Machine Learning in life sciences will be USD 1,950.30 million in 2025 with 59.7% share, projected to reach USD 14,620.50 million by 2034 at CAGR 28.7%, fueled by applications in clinical trial data analytics and drug optimization.

Top 5 Major Dominant Countries in the Machine Learning Segment

• United States: USD 750.20 million in 2025 with 38.4% share, projected at USD 5,620.10 million by 2034 at CAGR 28.8%, driven by pharma research investments.
• China: USD 450.30 million in 2025 with 23.1% share, forecasted at USD 3,390.20 million by 2034 at CAGR 28.7%, supported by AI innovation in biotech.
• Germany: USD 280.10 million in 2025 with 14.4% share, projected at USD 2,080.30 million by 2034 at CAGR 28.8%, fueled by EU-funded research programs.
• Japan: USD 250.40 million in 2025 with 12.8% share, forecasted at USD 1,860.50 million by 2034 at CAGR 28.7%, supported by drug discovery platforms.
• India: USD 219.30 million in 2025 with 11.3% share, projected at USD 1,670.20 million by 2034 at CAGR 28.7%, driven by clinical AI startups.

Deep Learning: Deep learning technologies held 42 percent of market share in 2024, underpinning generative AI and foundation models. More than 50 percent of new AI drug design platforms launched in 2024 used deep learning. Generative models created over 10,000 candidate compounds during pilot studies in 2025. Imaging analytics based on convolutional networks processed 100 million images across hospitals in 2024. Deep learning leads future innovation in artificial intelligence in life sciences market market insights.

Deep Learning in life sciences will be USD 1,314.69 million in 2025 with 40.3% share, projected to reach USD 10,114.89 million by 2034 at CAGR 28.9%, supported by precision medicine, imaging analysis, and genomics-based applications.

Top 5 Major Dominant Countries in the Deep Learning Segment

• United States: USD 510.20 million in 2025 with 38.8% share, projected at USD 3,920.40 million by 2034 at CAGR 28.9%, driven by clinical imaging adoption.
• China: USD 350.50 million in 2025 with 26.7% share, forecasted at USD 2,690.10 million by 2034 at CAGR 28.8%, supported by genomics data platforms.
• Germany: USD 190.40 million in 2025 with 14.5% share, projected at USD 1,460.20 million by 2034 at CAGR 28.9%, driven by healthcare AI firms.
• Japan: USD 150.30 million in 2025 with 11.4% share, forecasted at USD 1,160.40 million by 2034 at CAGR 28.8%, supported by hospital AI systems.
• United Kingdom: USD 113.29 million in 2025 with 8.6% share, projected at USD 880.10 million by 2034 at CAGR 28.9%, fueled by AI-led biotech innovation.

BY APPLICATION

Target Discovery: Target discovery represented 20 percent of market usage in 2024. More than 150 AI pipelines for target discovery were launched globally in 2023. AI platforms reduced candidate shortlists by 30 percent, cutting validation costs substantially. More than 100 protein or RNA targets were identified in single AI model runs. Target discovery remains an anchor for artificial intelligence in life sciences market market growth.

The Target Discovery application will be USD 1,360.40 million in 2025 with 41.7% share, projected to reach USD 10,310.30 million by 2034 at CAGR 28.7%, driven by AI-led genomics and biomarker discovery advancements.

Top 5 Major Dominant Countries in Target Discovery Application

• United States: USD 540.10 million in 2025 with 39.7% share, projected at USD 4,090.20 million by 2034 at CAGR 28.8%, driven by NIH-backed projects.
• China: USD 330.20 million in 2025 with 24.2% share, forecasted at USD 2,500.10 million by 2034 at CAGR 28.7%, supported by biopharma AI firms.
• Germany: USD 210.30 million in 2025 with 15.4% share, projected at USD 1,600.10 million by 2034 at CAGR 28.8%, driven by computational labs.
• Japan: USD 160.50 million in 2025 with 11.8% share, forecasted at USD 1,230.20 million by 2034 at CAGR 28.7%, supported by genetic AI adoption.
• India: USD 119.30 million in 2025 with 8.9% share, projected at USD 890.10 million by 2034 at CAGR 28.8%, fueled by contract research services.

Drug Discovery: Drug discovery was the largest application, with 32 percent of usage share in 2024. Over 300 AI collaborations in drug discovery were initiated in 2023, producing more than 1,000 new candidate molecules daily. Oncology pipelines accounted for 25 percent of drug discovery applications. AI reduced average screening time by 40 percent. This segment anchors artificial intelligence in life sciences market market outlook.

The Drug Discovery application will be USD 1,904.59 million in 2025 with 58.3% share, projected to reach USD 14,425.09 million by 2034 at CAGR 28.9%, fueled by AI platforms accelerating molecule design and clinical trial predictions.

Top 5 Major Dominant Countries in Drug Discovery Application

• United States: USD 720.20 million in 2025 with 37.8% share, projected at USD 5,450.10 million by 2034 at CAGR 28.9%, driven by pharma AI alliances.
• China: USD 480.10 million in 2025 with 25.2% share, forecasted at USD 3,650.20 million by 2034 at CAGR 28.8%, supported by biotech accelerators.
• Germany: USD 260.50 million in 2025 with 13.7% share, projected at USD 1,980.10 million by 2034 at CAGR 28.9%, driven by EU funding programs.
• Japan: USD 220.40 million in 2025 with 11.6% share, forecasted at USD 1,670.30 million by 2034 at CAGR 28.8%, supported by AI drug pipelines.
• United Kingdom: USD 223.39 million in 2025 with 11.7% share, projected at USD 1,670.20 million by 2034 at CAGR 28.9%, fueled by biotech startups.

Artificial Intelligence in Life Sciences Market Regional Outlook

North America led the artificial intelligence in life sciences market market with 49 percent share in 2024, supported by more than 500 AI deployments, 200 partnerships, and 58 percent cloud adoption across biopharma and research labs. Europe accounted for 25 to 30 percent, with Germany, the U.K., and France driving 60 percent of regional demand, 150 pilot programs launched, and infrastructure spending rising 12 percent in 2024. Asia-Pacific contributed 20 to 25 percent, led by China with 200 deployments and India with 100 pilots, reaching 60 percent cloud use and 50 government grants supporting AI in life sciences. Middle East & Africa represented 5 percent, with 20 projects in UAE, Saudi Arabia, South Africa, and Israel, 70 percent cloud reliance, 10 government initiatives, and 15 percent of deployments delayed by infrastructure and regulatory challenges.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commanded 49 percent share of the artificial intelligence in life sciences market market in 2024. More than 500 AI platforms were installed across U.S. and Canadian labs. Biopharma represented 54 percent of end-user demand in the region. Around 200 partnerships were signed in 2023 between AI providers and U.S. pharma. Cloud accounted for 58 percent of deployments. Infrastructure investments increased by 15 percent in 2024. North America remains the leading hub for artificial intelligence in life sciences market industry analysis.

North America AI in Life Sciences market will be USD 1,280.60 million in 2025 with 39.2% share, projected at USD 9,860.20 million by 2034 at CAGR 28.8%, driven by healthcare digitalization and strong AI ecosystem.

North America - Major Dominant Countries in the Artificial Intelligence in Life Sciences Market Market

• United States: USD 1,040.20 million in 2025 with 81.2% share, projected at USD 8,000.10 million by 2034 at CAGR 28.8%, driven by precision medicine.
• Canada: USD 140.40 million in 2025 with 11.0% share, forecasted at USD 1,080.20 million by 2034 at CAGR 28.7%, fueled by AI adoption in trials.
• Mexico: USD 70.30 million in 2025 with 5.5% share, projected at USD 540.20 million by 2034 at CAGR 28.8%, supported by biotech collaborations.
• Cuba: USD 15.10 million in 2025 with 1.2% share, forecasted at USD 110.30 million by 2034 at CAGR 28.7%, driven by health AI initiatives.
• Dominican Republic: USD 14.60 million in 2025 with 1.1% share, projected at USD 110.10 million by 2034

EUROPE

Europe accounted for 25 to 30 percent share in 2024. Germany, U.K., and France represented 60 percent of regional demand. More than 150 pilot programs were launched in 2023, with 20 percent focused on explainable AI. Cloud deployment reached 50 percent, hybrid systems 30 percent. Federated AI networks spanned 10 European countries. Infrastructure spending increased 12 percent in 2024. Europe sustains its position in artificial intelligence in life sciences market market share.

Europe AI in Life Sciences market will be USD 1,020.50 million in 2025 with 31.3% share, projected at USD 7,740.10 million by 2034 at CAGR 28.8%, supported by EU research funding and pharmaceutical partnerships.

Europe - Major Dominant Countries in the Artificial Intelligence in Life Sciences Market Market

• Germany: USD 420.20 million in 2025 with 41.2% share, projected at USD 3,200.30 million by 2034 at CAGR 28.8%, driven by research AI firms.
• France: USD 200.40 million in 2025 with 19.6% share, forecasted at USD 1,520.10 million by 2034 at CAGR 28.7%, supported by biotech collaborations.
• United Kingdom: USD 190.30 million in 2025 with 18.6% share, projected at USD 1,460.40 million by 2034 at CAGR 28.8%, driven by drug discovery AI.
• Italy: USD 110.20 million in 2025 with 10.8% share, forecasted at USD 840.30 million by 2034 at CAGR 28.7%, fueled by AI diagnostic adoption.
• Spain: USD 99.40 million in 2025 with 9.7% share, projected at USD 720.10 million by 2034 at CAGR 28.8%, supported by clinical trial AI tools.

ASIA-PACIFIC

Asia-Pacific achieved 20 to 25 percent of market share in 2024. China deployed 200 AI platforms, while India added 100 pilots. Quadrant AI adoption grew 22 percent regionally in 2024. Cloud accounted for 60 percent of deployments, edge AI 20 percent. Governments funded 50 grants in AI life sciences in 2024. Exports accounted for 10 percent of regional output. Asia-Pacific remains a central hub in artificial intelligence in life sciences market growth.

Asia-Pacific AI in Life Sciences market will be USD 780.40 million in 2025 with 23.9% share, projected at USD 5,880.20 million by 2034 at CAGR 28.9%, fueled by biotech startups, AI research, and healthcare digitalization.

Asia-Pacific - Major Dominant Countries in the Artificial Intelligence in Life Sciences Market Market

• China: USD 470.30 million in 2025 with 60.2% share, projected at USD 3,540.20 million by 2034 at CAGR 28.9%, supported by national AI policies.
• Japan: USD 190.40 million in 2025 with 24.4% share, forecasted at USD 1,430.20 million by 2034 at CAGR 28.8%, driven by genomic AI platforms.
• India: USD 90.50 million in 2025 with 11.6% share, projected at USD 690.40 million by 2034 at CAGR 28.9%, fueled by healthcare AI startups.
• South Korea: USD 20.20 million in 2025 with 2.6% share, forecasted at USD 160.10 million by 2034 at CAGR 28.8%, supported by hospital AI systems.
• Australia: USD 9.00 million in 2025 with 1.2% share, projected at USD 60.10 million by 2034 at CAGR 28.7%, driven by biotech AI initiatives.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for 5 percent share in 2024. About 20 AI projects were active in UAE, Saudi Arabia, South Africa, and Israel. Cloud dominated 70 percent of deployments. Around 10 government programs supported AI trials in 2024. Cold chain and data limitations delayed 15 percent of potential deployments. Regulatory uncertainty affected 12 percent of projects. The region is gradually emerging within artificial intelligence in life sciences market market opportunities.

Middle East & Africa AI in Life Sciences market will be USD 183.49 million in 2025 with 5.6% share, projected at USD 1,255.09 million by 2034 at CAGR 28.8%, supported by healthcare modernization and rising AI adoption.

Middle East & Africa - Major Dominant Countries in the Artificial Intelligence in Life Sciences Market Market

• Saudi Arabia: USD 60.20 million in 2025 with 32.8% share, projected at USD 410.20 million by 2034 at CAGR 28.8%, driven by Vision 2030 initiatives.
• UAE: USD 50.30 million in 2025 with 27.4% share, forecasted at USD 340.40 million by 2034 at CAGR 28.7%, fueled by healthcare AI investment.
• South Africa: USD 40.10 million in 2025 with 21.8% share, projected at USD 280.30 million by 2034 at CAGR 28.8%, supported by biotech research.
• Egypt: USD 20.40 million in 2025 with 11.1% share, forecasted at USD 150.10 million by 2034 at CAGR 28.7%, driven by AI diagnostic systems.
• Nigeria: USD 12.49 million in 2025 with 6.9% share, projected at USD 74.09 million by 2034 at CAGR 28.8%, supported by healthcare digitalization.

List of Top Artificial Intelligence in Life Sciences Companies

• OWKIN
• BenevolentAI
• IBM Watson
• Massachusetts Institute of Technology
• QUANTUMBLACK
• RECURSION
• Atomwise
• Exscintia
• XtalPi
• Intel
• flatiron
• Syapse
• PathAI
• WINTERLIGHT

Top two by market share:

• OWKIN: Controls 10 to 12 percent of global share, specializing in federated learning and biomarker discovery.
• BenevolentAI: Holds 8 to 10 percent of share, strong in drug discovery pipelines and licensing models.

Investment Analysis and Opportunities

Investments in artificial intelligence in life sciences market market remain strong, with more than 200 venture deals completed between 2023 and 2025. Around 10 percent of life sciences capital expenditures were allocated to AI platforms. Development of foundation models required up to USD 10 million in compute costs. More than 300 partnerships were signed in 2023 across biopharma and technology providers. Cloud infrastructure spending increased 15 percent in 2024, while federated learning networks expanded in 10 global regions. Asia and Latin America accounted for less than 10 percent penetration, offering a 20 percent upside potential.

New Product Development

New products in artificial intelligence in life sciences market market reflect innovation in generative AI, foundation models, explainability, and hybrid inference. More than five new foundation models tailored for protein folding were launched in 2024. Generative platforms produced over 10,000 novel compounds in 2025. Federated learning frameworks processed one million patient records without raw data transfers across 10 hospital consortia. Hybrid systems combining cloud and edge deployments captured 25 percent of new launches. Explainability modules were embedded in 30 percent of tools in 2025.

Five Recent Developments

• In 2024, OWKIN signed a biomarker AI deal worth USD 180 million with a global pharma firm.
• In 2025, BenevolentAI expanded target discovery pipelines to cover 50 new disease categories.
• In 2024, QuantumBlack introduced explainability modules adopted by 10 European pharma companies.
• In 2025, Atomwise generated 5,000 new compounds, advancing 20 toward preclinical trials.
• In 2023, IBM Watson completed 100 clinical trial AI engagements worldwide.

Report Coverage

The artificial intelligence in life sciences market market report provides segmentation by type, application, offering, deployment, and region. Types include machine learning (29.6 percent) and deep learning (42 percent). Applications include target discovery (20 percent) and drug discovery (32 percent). Offering segmentation was led by software at 55 percent, followed by services at 30 percent and hardware at 15 percent. Deployment favored cloud with 58 percent share, hybrid with 30 percent, and on-premise with 12 percent. Regional distribution was led by North America at 49 percent, Europe at 25 to 30 percent, Asia-Pacific at 20 to 25 percent, and Middle East & Africa at 5 percent.

Artificial Intelligence in Life Sciences Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4205.31 Million in 2026
Market Size Value By	USD 31859.18 Million by 2035
Growth Rate	CAGR of 28.8% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Machine Learning Deep Learning By Application : Target Discovery Drug Discovery
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample